Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Gilead Sciences Ltd
Flowers Building, Granta Park, Abington, Cambridge, Cambridge, CB21 6GT, UK
Telephone: +44 (0)1223 897 300
Fax: +44 (0)1223 897 291
Medical Information Direct Line: +44 (0)1223 897 555
Medical Information e-mail: ukmedinfo@gilead.com
Customer Care direct line: +44 (0)1223 897 400
Medical Information Fax: +44 (0)1223 897 281

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 16/12/2011
PIL Atripla 600 mg/200 mg/245 mg film coated tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 16/12/2011 and displayed until Current
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 05/09/2011 and displayed until 16/12/2011
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
  • Change to, or new, use for medicine
  • Change to warnings or special precautions for use
  • Change to information about pregnancy or lactation
Updated on 24/01/2011 and displayed until 05/09/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 07/12/2009 and displayed until 24/01/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to manufacturer contact details
Updated on 21/04/2009 and displayed until 07/12/2009
Reasons for adding or updating:
  • Change to date of revision
Updated on 21/01/2009 and displayed until 21/04/2009
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions
Updated on 12/09/2008 and displayed until 21/01/2009
Reasons for adding or updating:
  • Change to drug interactions
  • Introduction of new pack/pack size
Updated on 09/06/2008 and displayed until 12/09/2008
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 26/03/2008 and displayed until 09/06/2008
Reasons for adding or updating:
  • Change of manufacturer
  • Company name change or merger
  • Change to Further Information section
Updated on 08/01/2008 and displayed until 26/03/2008
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
  tenofovir disoproxil fumarate
  efavirenz
  emtricitabine